BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2014 6:36:00 PM | Browse: 1354 | Download: 1517
 |
Received |
|
2014-02-22 17:37 |
|
Peer-Review Started |
|
2014-02-22 19:50 |
|
To Make the First Decision |
|
2014-03-27 21:13 |
|
Return for Revision |
|
2014-03-31 10:12 |
|
Revised |
|
2014-04-29 00:00 |
|
Second Decision |
|
2014-05-26 21:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2014-05-26 21:52 |
|
Articles in Press |
|
2014-05-26 22:07 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-10-10 15:08 |
|
Publish the Manuscript Online |
|
2014-10-20 18:35 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tahereh Ghaziani, Hossein Sendi, Saeid Shahraz, Philippe Zamor and Herbert L Bonkovsky |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| United States National Institutes of Health |
R15 HL 117199 (to Bonkovsky HL) |
| United States National Institutes of Health |
U01 DK 065201 (to Bonkovsky HL) |
| institutional funds from Carolinas HealthCare System |
to Sendi H |
| Beth Israel Deaconess Medical Center |
to Ghaziani T |
|
| Corresponding Author |
Herbert L Bonkovsky, MD, Professor, Senior Adviser, The Liver-Biliary-Pancreatic Center, Department of Medicine, Carolinas HealthCare System, MMP1, 6th Floor, 1025 Morehead Medical Center Drive, Charlotte, NC 28204, United States. herbert.bonkovsky@carolinas.org |
| Key Words |
Cirrhosis; End-stage liver disease; Entecavir; Genetic variants; Hepatocellular carcinoma; Hepatitis B; Interferon alpha; Lamivudine; Liver transplantation; Tenofovir |
| Core Tip |
Hepatitis B viral (HBV) infection continues to be a major health problem world-wide. Recurrence of HBV following liver transplantation was a major problem in the 1980’s-1990’s, which led most insurers to refuse to cover costs of such transplants. This changed dramatically following the landmark demonstration that high-dose hepatitis B immune globulin (HBIG) could prevent recurrent infection. Recently, highly effective inhibitors of the HBV polymerase, with high barrier to resistance (entecavir, tenofovir) have become available, and they promise to decrease the need for HBIG and the costs and complexity of preventing recurrent HBV after liver transplantation. |
| Publish Date |
2014-10-20 18:35 |
| Citation |
Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i39/14142.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i39.14142 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
